Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260379 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2AMEN1PKMHTT | |
| SCHEMBL10781853 | 0.85 | ALDH1A1 (0.53) | SMN1; SMN2KMT2AMEN1RAB9AMAPT | |
| SCHEMBL8682896 | 0.82 | LMNA (0.60) | SMN1; SMN2KMT2AMEN1PKMHPGD | |
| SCHEMBL1162140 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2KMT2AMEN1HTTRAB9A | |
| SCHEMBL1162142 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2KMT2AMEN1HTTRAB9A | |
| SCHEMBL10971917 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2KMT2AMEN1PKMHTT | |
| SCHEMBL9804683 | 0.79 | SMN1; SMN2 (0.54) | SMN1; SMN2KMT2AMEN1PKMHTT | |
| SCHEMBL9804687 | 0.79 | SMN1; SMN2 (0.54) | SMN1; SMN2KMT2AMEN1PKMHTT | |
| SCHEMBL6341024 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AMEN1HPGDATM | |
| SCHEMBL6341025 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AMEN1HPGDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653073-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2014-02-18 | — | — | US | disclosed |
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2013-12-12 | — | — | US | disclosed |
| US-8541412-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-09-24 | — | — | US | disclosed |
| US-8133889-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-03-13 | — | — | US | disclosed |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-02-23 | — | — | US | disclosed |
| CN-101987848-A | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB | 2011-03-23 | — | — | CN | disclosed |
| US-20110034460-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CYP11B1, SDHA, CYP11B2 | SMN1; SMN2 2931/4885KMT2A 3326/4885MEN1 661/4885 |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | CYP11B1, SDHA, CYP11B2 | SMN1; SMN2 2931/4885KMT2A 3326/4885MEN1 661/4885 |
| US-20110034460-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | CYP11B1, SDHA, CYP11B2 | SMN1; SMN2 2931/4885KMT2A 3326/4885MEN1 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.